Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now official registry

Unspecified Adult Solid Tumor, Protocol Specific clinical trials

5 of 112 indexed Unspecified Adult Solid Tumor, Protocol Specific trials are currently recruiting.

112 US clinical trials · 5 currently recruiting

Unspecified Adult Solid Tumor, Protocol Specific is the subject of 112 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 10 are in Phase 3-4 (later-stage) and 93 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 26 of these trials.

The research picture

Unspecified Adult Solid Tumor, Protocol Specific has 112 registered US clinical trials, 5 of them open to new participants right now, about 4% of the total.

5
recruiting participants now
4%
of trials open to enrollment
10
in Phase 3–4 (later-stage)
26
top sponsor: National Cancer Institute (NCI)
Phase 185Phase 28Phase 310

Active & Recent Trials

112 total, page 1 of 3

RECRUITING 20,000 participants

Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors

Wake Forest University Health Sciences

NCT00900471

RECRUITING 10,000 participants

Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants

University of Texas Southwestern Medical Center

NCT00992303

RECRUITING 3,000 participants

Registry of Older Patients With Cancer

UNC Lineberger Comprehensive Cancer Center

NCT01137825

RECRUITING 100 participants

Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors

Stanford University

NCT02215928

RECRUITING

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Barbara Ann Karmanos Cancer Institute

NCT00935090

ACTIVE NOT RECRUITING NA 1,062 participants

Assessment Tool for Older Patients With Cancer

City of Hope Medical Center

NCT00477958

ACTIVE NOT RECRUITING Phase 1 12 participants

RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists

City of Hope Medical Center

NCT02112565

COMPLETED Phase 3 1,428 participants

APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer

Heron Therapeutics

NCT00343460

COMPLETED Phase 3 600 participants

Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone

Novartis

NCT00003884

COMPLETED Phase 3 502 participants

Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer

Mayo Clinic

NCT00661999

COMPLETED Phase 3 472 participants

Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer

Radiation Therapy Oncology Group

NCT00053053

COMPLETED Phase 3 376 participants

Levocarnitine in Treating Fatigue in Cancer Patients

ECOG-ACRIN Cancer Research Group

NCT00091169

COMPLETED Phase 2 361 participants

Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer

Roswell Park Cancer Institute

NCT00003816

COMPLETED Phase 3 231 participants

Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

Alliance for Clinical Trials in Oncology

NCT00489411

COMPLETED Phase 3 227 participants

(Valerian) for Improving Sleep in Patients With Cancer Receiving Adjuvant Therapy

Alliance for Clinical Trials in Oncology

NCT00075842

COMPLETED Phase 2 226 participants

Cognitive Behavioral Therapy With or Without Armodafinil in Treating Cancer Survivors With Insomnia and Fatigue After Chemotherapy

Abramson Cancer Center at Penn Medicine

NCT01019187

COMPLETED Phase 3 148 participants

Methylphenidate in Treating Patients With Fatigue Caused by Cancer

Alliance for Clinical Trials in Oncology

NCT00376675

COMPLETED Phase 1 140 participants

Irinotecan in Treating Aging Patients With Solid Tumors

Alliance for Clinical Trials in Oncology

NCT00026195

COMPLETED NA 140 participants

White Wine or Nutritional Supplement in Improving Appetite in Patients With Cancer

Academic and Community Cancer Research United

NCT00936728

COMPLETED Phase 2 109 participants

Docetaxel in Treating Patients With Solid Tumors

Alliance for Clinical Trials in Oncology

NCT00003565

COMPLETED Phase 1 96 participants

PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

NCT00028587

COMPLETED 93 participants

Assessing Older Patients With Cancer

Alliance for Clinical Trials in Oncology

NCT00416481

COMPLETED Phase 1 80 participants

Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors

National Cancer Institute (NCI)

NCT00058253

COMPLETED Phase 1 78 participants

Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

NCT00047047

COMPLETED Phase 1 73 participants

Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors

Memorial Sloan Kettering Cancer Center

NCT00003004

COMPLETED Early Phase 1 65 participants

Fludeoxyglucose F 18 PET/CT Imaging in Finding Cancer in Patients Undergoing Surgery for Solid Tumors

Ohio State University Comprehensive Cancer Center

NCT00816335

COMPLETED Phase 1 64 participants

Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer

University of California, Davis

NCT00408499

COMPLETED Phase 1 60 participants

2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

NCT00028821

COMPLETED Phase 1 59 participants

Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor

Northwestern University

NCT00711243

COMPLETED Phase 1 54 participants

Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors

National Cancer Institute (NCI)

NCT00138177

COMPLETED Phase 1 54 participants

Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

City of Hope Medical Center

NCT00541359

COMPLETED Phase 1 52 participants

1-Methyl-D-Tryptophan in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

NCT00567931

COMPLETED Phase 1 50 participants

EF5 in Treating Patients With Solid Tumors

National Cancer Institute (NCI)

NCT00003282

COMPLETED Phase 1 50 participants

LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function

The University of Texas Health Science Center at San Antonio

NCT00003706

COMPLETED Phase 1 50 participants

Sorafenib and Bortezomib in Treating Patients With Advanced Cancer

National Cancer Institute (NCI)

NCT00303797

COMPLETED Phase 1 47 participants

Docetaxel and Irinotecan in Treating Patients With Advanced Solid Tumors

Yale University

NCT00004923

COMPLETED Phase 1 45 participants

Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

National Cancer Institute (NCI)

NCT00030368

COMPLETED Phase 1 45 participants

Calcitriol Plus Paclitaxel in Treating Patients With Advanced Solid Tumors

University of Pittsburgh

NCT00009802

COMPLETED Phase 2 44 participants

S0916, MLN1202 in Treating Patients With Bone Metastases

SWOG Cancer Research Network

NCT01015560

COMPLETED Phase 1 44 participants

Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide

H. Lee Moffitt Cancer Center and Research Institute

NCT00006047

COMPLETED Phase 1 44 participants

PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma

Cellxpert Biotechnology

NCT00073892

COMPLETED Phase 1 44 participants

Tirapazamine, Carboplatin, and Paclitaxel in Treating Patients With Advanced Malignant Solid Tumors

City of Hope Medical Center

NCT00005078

COMPLETED Phase 1 43 participants

Safingol and Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Memorial Sloan Kettering Cancer Center

NCT00084812

COMPLETED Phase 1 40 participants

L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors

Memorial Sloan Kettering Cancer Center

NCT00003430

COMPLETED Phase 1 40 participants

Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers

National Cancer Institute (NCI)

NCT00074308

COMPLETED Phase 1 40 participants

Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors

National Cancer Institute (NCI)

NCT00255658

COMPLETED Phase 1 40 participants

UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants

National Cancer Institute (NCI)

NCT00098969

COMPLETED Phase 1 40 participants

GTI-2040 and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors

National Cancer Institute (NCI)

NCT00078962

COMPLETED Phase 1 40 participants

Ro 31-7453 in Treating Patients With Locally Advanced or Metastatic Solid Tumor

Memorial Sloan Kettering Cancer Center

NCT00003755

COMPLETED Phase 1 38 participants

Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors

Abramson Cancer Center at Penn Medicine

NCT00714181

Page 1 of 3 Next →

Phase Distribution

PhaseTrial count
Phase 1 85
Phase 2 8
Phase 3 10

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Reading the Unspecified Adult Solid Tumor, Protocol Specific Trial Landscape

112 indexed Unspecified Adult Solid Tumor, Protocol Specific studies · 5 recruiting (4%).

Phase mix: 10 late (III/IV) vs 93 early (I/II).

Top sponsor: National Cancer Institute (NCI) (26 trials), 9 others listed. 50 shown below, recruiting first.

How to read this condition's trial landscape

That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.

Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.

All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation, eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.

Frequently Asked Questions

How many clinical trials are there for Unspecified Adult Solid Tumor, Protocol Specific?

PlainTrial tracks 112 US clinical trials for Unspecified Adult Solid Tumor, Protocol Specific, of which 5 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Unspecified Adult Solid Tumor, Protocol Specific?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.